Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced today that it has signed a co-development agreement with PathGroup for the PGDx Elio tissue-based complete assay.

As part of the agreement, the firms will partner on the necessary studies to support and secure US regulatory approval for the Elio tissue complete assay. PathGroup said it plans to be the first US laboratory to use the Elio panel.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
17

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.